Compare BL & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BL | DMRA |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2016 | 2020 |
| Metric | BL | DMRA |
|---|---|---|
| Price | $29.95 | $29.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $56.62 | $43.00 |
| AVG Volume (30 Days) | ★ 1.3M | 836.6K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $177,031,000.00 | N/A |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $10.90 | N/A |
| P/E Ratio | $229.85 | ★ N/A |
| Revenue Growth | ★ 43.78 | N/A |
| 52 Week Low | $24.70 | $16.50 |
| 52 Week High | $59.57 | $30.19 |
| Indicator | BL | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 70.50 |
| Support Level | $29.23 | $22.71 |
| Resistance Level | $31.23 | N/A |
| Average True Range (ATR) | 1.33 | 2.42 |
| MACD | 0.37 | 0.91 |
| Stochastic Oscillator | 95.93 | 98.09 |
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.